Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- 10 November 2015
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 112 (47), E6506-E6514
- https://doi.org/10.1073/pnas.1519623112
Abstract
Signaling through the immune checkpoint programmed cell death protein-1 (PD-1) enables tumor progression by dampening antitumor immune responses. Therapeutic blockade of the signaling axis between PD-1 and its ligand programmed cell death ligand-1 (PD-L1) with monoclonal antibodies has shown remarkable clinical success in the treatment of cancer. However, antibodies have inherent limitations that can curtail their efficacy in this setting, including poor tissue/tumor penetrance and detrimental Fc-effector functions that deplete immune cells. To determine if PD-1:PD-L1–directed immunotherapy could be improved with smaller, nonantibody therapeutics, we used directed evolution by yeast-surface display to engineer the PD-1 ectodomain as a high-affinity (110 pM) competitive antagonist of PD-L1. In contrast to anti–PD-L1 monoclonal antibodies, high-affinity PD-1 demonstrated superior tumor penetration without inducing depletion of peripheral effector T cells. Consistent with these advantages, in syngeneic CT26 tumor models, high-affinity PD-1 was effective in treating both small (50 mm3) and large tumors (150 mm3), whereas the activity of anti–PD-L1 antibodies was completely abrogated against large tumors. Furthermore, we found that high-affinity PD-1 could be radiolabeled and applied as a PET imaging tracer to efficiently distinguish between PD-L1–positive and PD-L1–negative tumors in living mice, providing an alternative to invasive biopsy and histological analysis. These results thus highlight the favorable pharmacology of small, nonantibody therapeutics for enhanced cancer immunotherapy and immune diagnostics.Keywords
Funding Information
- Virginia and D.K. Ludwig Fund for Cancer Research (1)
- HHS | NIH | National Cancer Institute (P50A114747)
- Canary Foundation (2)
- HHS | NIH | National Cancer Institute (T32CA09151)
- HHS | NIH | National Institute of General Medical Sciences (GM07365)
- Cancer Research Institute (3)
This publication has 33 references indexed in Scilit:
- The determinants of tumour immunogenicityNature Reviews Cancer, 2012
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityThe Journal of Experimental Medicine, 2010
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumorsBMC Cancer, 2010
- Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing MoleculesPublished by The American Association of Immunologists ,2010
- Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Positive Tumor with a 64Cu Labeled Affibody ProteinBioconjugate Chemistry, 2010
- B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturationProceedings of the National Academy of Sciences of the United States of America, 2009